Bob Valamehr

Bob Valamehr

Company: Fate Therapeutics

Job title: CDO

Bio:

Bob Valamehr is the Chief Development Officer at Fate Therapeutics, overseeing the company’s early development activities including “off-the-shelf” cell therapy products derived from the company’s induced pluripotent stem cell platform. Previously, Dr. Valamehr was the Vice President of Cancer Immunotherapy at Fate and prior to that played key scientific roles at Amgen, the Center for Cell Control (a NIH Nanomedicine Development Center) and the Broad Stem Cell Research Center developing novel methods to control pluripotency, to modulate stem cell fate including hematopoiesis and to better understand cellular signaling pathways associated with cancer. He has co-authored numerous studies and patents related to stem cell biology, oncology and materials science. Dr. Valamehr received his Ph.D. from the Department of Molecular and Medical Pharmacology at UCLA, his M.B.A. from Pepperdine University and his B.S. from the Department of Chemistry and Biochemistry at UCLA.

Seminars:

Prospects for Multi-targeting Off-the-Shelf CAR-NK Cells 9:40 am

Describing renewable engineered master cell lines for off-the-shelf adoptive NK cell therapy Discussing a unique approach to utilize both chimeric antigen receptor and CD16 Fc receptor to create a multi-antigen targeting approach in cancer immunotherapy Outlining techniques to enhance persistence and expansion capabilities of NK cellsRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.